We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 84.00 | 0.75% | 11,352.00 | 11,350.00 | 11,352.00 | 11,412.00 | 11,288.00 | 11,288.00 | 3,579,740 | 16:29:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.55 | 175.98B |
From Apr 2019 to Apr 2024
TIDMAZN
RNS Number : 3556R
AstraZeneca PLC
26 June 2015
AstraZeneca PLC - Change in ADS ratio
AstraZeneca PLC (the "Company") today announces an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The expected effective date for the ratio change is 27 July 2015. There will be no change to the underlying Ordinary Shares.
ADS holders at the close of business New York time on the record date, 22 July 2015, will receive a distribution of one additional ADS for every ADS held. The new ADSs are expected to be distributed on 24 July 2015. No action is required by ADS holders to effect this change.
Contact details for Citibank, N.A., the Company's ADR depositary, can be found below.
A C N Kemp
Company Secretary
26 June 2015
CONTACT
Citibank Shareholder Services
PO Box 43077 Tel (toll free in the US): +1-888-697-8018 Providence Tel (outside the US): +1-781-575-4555 RI 02940-3077 US
Media Enquiries
Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Michele Meixell + 1 302 885 6351 (US)
Investor Enquiries
Hot Features
Premium
UK
Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185
Eugenia Litz Respiratory, Inflammation +44 20 7604 8233 mob: +44 7884 735627
and Autoimmunity
Nick Stone Cardiovascular +44 1763 263 mob: +44 7717 618834
and 994
Metabolic Disease
Karl Hård Oncology +44 20 7604 8123 mob: +44 7789 654364
Craig Marks Infection, Neuroscience +44 20 7604 8591 mob: +44 7881 615764
and Gastrointestinal
Disease
Christer Gruvris +44 20 7604 8126 mob: +44 7827 836825
US
Dial / Toll-Free 301-398-3251 866-381-7277
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFFIRIIRFIE
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
